ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO160

The Impact of Carbon Monoxide Poisoning on Long-Term Risk of CKD: A Nationwide, Population-Based Study in Taiwan

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Wei, Kuangyu, Tri-service general hospital, National defense medical center , Taipei, Taiwan
  • Liao, Chen-Yi, Tri-service general hospital, National defense medical center , Taipei, Taiwan
  • Wu, Chia-chao, Tri-service general hospital, National defense medical center , Taipei, Taiwan

Risk of chronic kidney disease (CKD) in patients with carbon monoxide poisoning (COP) and the hyperbaric oxygen (HBO) therapeutic effect had not been investigated.


Patients that survived after COP during index hospitalizations from 2000 to 2013 were identified in nationwide administrative registries. In a cohort study of 989,753 patients, we enrolled 8,616 COP patients and matched 34,464 comparison cohort as the non-COP group by propensity scores. Using this adjusted data, a possible association between COP and the risk of developing CKD was estimated using a Cox proportional hazard regression model. We further compared cumulative risk of CKD among COP patients stratified by HBOT with Kaplan-Meier analysis and the log-rank test.


After a mean follow-up period of 4.28 years, the incident CKD rate was 261 per 10000 person-years. The COP group had higher risk (adjusted hazard ratio: 6.150; P < 0.001) than the non- COP group when measured over 4 years after CKD diagnosis. After stratification, the risk of CKD remarkably increased independent of status regarding sex, age, season and comorbidities (hypertension, diabetes mellitus, congestive heart failure, stroke, chronic obstructive pulmonary disease, liver cirrhosis, coronary artery disease, arrhythmia or hyperlipidemia) in the COP cohort. Age-specific COP to non-COP hazard was the greatest in the youngest group (18-29 years) (adjusted HR=34.18, 95% CI = 29.47–39.653). Additionally, HBOT did not result in statistically significant reduction in the risk of CKD in the COP cohorts (P=0.188, long-rank test).


The patients that survived after COP had a higher incidence of developing CKD. The results suggest that clinicians should enhance postdischarge follow-up of kidney function among COP patients